BioPort anthrax vaccine production
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
HHS Special Assistant for National Security and Emergency Management Scott Lillibridge, MD, tells a Senate Appropriations/HHS Subcommittee hearing Oct. 3 that BioPort may begin production of its anthrax vaccine shortly, "perhaps as soon as six weeks." BioPort previously said it would submit a plan for renovation of its Michigan anthrax vaccine plant in mid-October and that it expected FDA review to take four to six months. The firm, the sole U.S. manufacturer of anthrax vaccine, supplies the product to the Department of Defense